...
首页> 外文期刊>Biochemical Pharmacology >The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.
【24h】

The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

机译:小鼠纹状体多巴胺能末端的烟碱型乙酰胆碱受体亚型。

获取原文
获取原文并翻译 | 示例

摘要

This review summarizes studies that attempted to determine the subtypes of nicotinic acetylcholine receptors (nAChR) expressed in the dopaminergic nerve terminals in the mouse. A variety of experimental approaches has been necessary to reach current knowledge of these subtypes, including in situ hybridization, agonist and antagonist binding, function measured by neurotransmitter release from synaptosomal preparations, and immunoprecipitation by selective antibodies. Early developments that facilitated this effort include the radioactive labeling of selective binding agents, such as [(125)I]-alpha-bungarotoxin and [(3)H]-nicotine, advances in cloning the subunits, and expression and evaluation of function of combinations of subunits in Xenopus oocytes. The discovery of epibatidine and alpha-conotoxin MII (alpha-CtxMII), and the development of nAChR subunit null mutant mice have been invaluable in determining which nAChR subunits are important for expression and function in mice, as well as allowing validation of the specificity of subunit specific antibodies. These approaches have identified five nAChR subtypes of nAChR that are expressed on dopaminergic nerve terminals. Three of these contain the alpha6 subunit (alpha4alpha6beta2beta3, alpha6beta2beta3, alpha6beta2) and bind alpha-CtxMII with high affinity. One of these three subtypes (alpha4alpha6beta2beta3) also has the highest sensitivity to nicotine of any native nAChR that has been studied, to date. The two subtypes that do not have high affinity for alpha-CtxMII (alpha4beta2, alpha4alpha5beta2) are somewhat more numerous than the alpha6* subtypes, but do bind nicotine with high affinity. Given that our first studies detected readily measured differences in sensitivity to agonists and antagonists among these five nAChR subtypes, it seems likely that subtype selective compounds could be developed that would allow therapeutic manipulation of diverse nAChRs that have been implicated in a number of human conditions.
机译:这篇综述总结了试图确定小鼠多巴胺能神经末梢中表达的烟碱型乙酰胆碱受体(nAChR)亚型的研究。为了获得这些亚型的最新知识,必须采取多种实验方法,包括原位杂交,激动剂和拮抗剂结合,通过突触体制剂释放神经递质测量的功能以及选择性抗体的免疫沉淀。促进这项工作的早期发展包括放射性标记选择性结合剂,例如[(125)I]-α-邦格鲁毒素和[(3)H]-烟碱,克隆亚基以及表达和评估其功能爪蟾卵母细胞亚基的组合。 Epibatidine和α-芋螺毒素MII(alpha-CtxMII)的发现以及nAChR亚基无效突变小鼠的发展对于确定哪些nAChR亚基对于小鼠中的表达和功能非常重要,并且可以验证其特异性。亚基特异性抗体。这些方法已经确定了在多巴胺能神经末梢表达的nAChR的五个nAChR亚型。其中三个包含alpha6亚基(alpha4alpha6beta2beta3,alpha6beta2beta3,alpha6beta2),并以高亲和力结合alpha-CtxMII。迄今为止,这三种亚型之一(alpha4alpha6beta2beta3)对尼古丁的敏感性最高。对alpha-CtxMII没有高亲和力的两个亚型(alpha4beta2,alpha4alpha5beta2)比alpha6 *亚型要多得多,但它们确实以高亲和力结合尼古丁。鉴于我们的第一项研究发现了这五种nAChR亚型中对激动剂和拮抗剂的敏感性的容易测量的差异,看来可能开发出亚型选择性化合物,从而允许对涉及多种人类疾病的多种nAChRs进行治疗性操作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号